Introduction: The clinical course of late-onset Pompe disease is heterogeneous, and new clinical outcome measures are needed to evaluate enzyme replacement therapy (ERT). Methods: We correlated the 6-Minute Walk Test (6MWT), Walton and Gardner-Medwin (WGM) score, and GSGC (Gait, Stairs, Gower, Chair) scores in 40 patients. Results: At baseline, the GSGC score correlated with both WGM (P < 0.001, n = 33) and 6MWT (P < 0.001, n = 26). After 1 year of ERT, we observed a significant change in gait, stairs and chair performance on the GSGC scale. The 6MWT significantly increased from 319 to 371 meters in 32 patients, and the WGM score was reduced. Conclusions: GSGC is a group of functional tests that requires only a few minutes to perform, therefore, this score might be a good indicator to be used in future studies. © 2012 Wiley Periodicals, Inc.

New motor outcome function measures in evaluation of Late-Onset Pompe disease before and after enzyme replacement therapy

Piras, R.
Membro del Collaboration Group
;
2012-01-01

Abstract

Introduction: The clinical course of late-onset Pompe disease is heterogeneous, and new clinical outcome measures are needed to evaluate enzyme replacement therapy (ERT). Methods: We correlated the 6-Minute Walk Test (6MWT), Walton and Gardner-Medwin (WGM) score, and GSGC (Gait, Stairs, Gower, Chair) scores in 40 patients. Results: At baseline, the GSGC score correlated with both WGM (P < 0.001, n = 33) and 6MWT (P < 0.001, n = 26). After 1 year of ERT, we observed a significant change in gait, stairs and chair performance on the GSGC scale. The 6MWT significantly increased from 319 to 371 meters in 32 patients, and the WGM score was reduced. Conclusions: GSGC is a group of functional tests that requires only a few minutes to perform, therefore, this score might be a good indicator to be used in future studies. © 2012 Wiley Periodicals, Inc.
2012
Enzyme replacement therapy; Glycogen storage type II; Outcome measures; Protocol; Trial; Adult; Age of Onset; Aged; Female; Follow-Up Studies; Gait; Glycogen Storage Disease Type II; Humans; Male; Middle Aged; Motor Activity; Treatment Outcome; Walking; Disability Evaluation; Enzyme Replacement Therapy; Outcome Assessment (Health Care); Physiology; Neurology (clinical); Cellular and Molecular Neuroscience; Physiology (medical)
File in questo prodotto:
File Dimensione Formato  
mus.23340 (3).pdf

Solo gestori archivio

Tipologia: versione editoriale (VoR)
Dimensione 773.27 kB
Formato Adobe PDF
773.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/235688
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 52
social impact